This trial is evaluating whether Pembrolizumab will improve 1 primary outcome and 1 secondary outcome in patients with Relapse. Measurement will happen over the course of 6 months from start of treatment.
This trial requires 40 total participants across 2 different treatment groups
This trial involves 2 different treatments. Pembrolizumab is the primary treatment being studied. Participants will be divided into 2 treatment groups. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
"A variety of treatments are used for GLI: surgery, chemotherapy, radiation, targeted drugs, and combinations thereof. These treatments are often used by many patients over different time frames." - Anonymous Online Contributor
"The American Cancer Society estimates 7,040 to 10,910 people will develop glioblastoma a year in the United States. This disease has a poor prognosis and occurs primarily in older men." - Anonymous Online Contributor
"More work is needed to identify patient populations who would have a substantial benefit from clinical trial enrollment and to develop and implement clinical trial protocols. We recommend a clinical trial for children if there are familial members with glioblastoma (Gli2401." - Anonymous Online Contributor
"The authors conclude that the data suggests that the glioblastoma may be cured with a single course of therapy. However, this may not be appropriate strategy in all subsets of patients, and may not be sufficient for a complete cure. Furthermore, the authors do not recommend a treatment that may be curative in all patients with glioblastoma in the absence of adverse event risks. The authors recommend a more tailored treatment plan based on clinical and imaging assessments and should not seek to cure patients with glioblastoma unless they are able to control adverse events with the therapy." - Anonymous Online Contributor
"Glioblastoma is a tumour in the brain. The tumour usually starts in children under 10 years old and often spreads out from the lining of the base of the brain to form a solid mass. The tumour may have a number of symptoms. Most children die 6 to 12 months after they are diagnosed.\n" - Anonymous Online Contributor
"Most tumors are slow to grow (average size about four cm) which may take between 6 years and almost 20 years to grow to the size of an average human brain. It is important for a person to pay special attention to symptoms, signs, and signs of a tumor that could be a sign of a tumor or malignant brain disease like glioblastoma. This information may help to choose how an individual can best manage their tumor as well as their chances of being cured or having a long-lived remission. The prognosis of a glial tumor depends on if it has grown to a large size with signs of compression (infiltration), is the glioma in a person's brain or spinal cord." - Anonymous Online Contributor
"There are different factors which contribute to the initiation of glioma. This includes not only genetic factors but also environmental factors. Overall, the main risk factors are age, ionizing radiation and the exposure to alimentary and occupational carcinogens. Additionally, the interaction of more than one of these risk factors have also contributed to this malignancy. The genetic predisposition seems also strongly influence this malignancy, although it is debated. Smoking behaviour also influences the development of glioma. These are the biggest risk factors for the future development of the patient with a malignancy." - Anonymous Online Contributor
"Glioblastoma is the most common malignant brain tumor in children and young adults. It is especially common in the developing world, particularly Africa, India, Bangladesh and the Middle East. However, it is not limited to these regions and also occurs in the Western world. Most often it is diagnosed in people under 30 years of age and is associated with a worse prognosis compared to other primary brain cancers. It is found in both sexes." - Anonymous Online Contributor
"Pembrolizumab is an FDA-approved immunotherapy to treat a large panel of tumors and is the first-in-class anti-PD-1 antibody. In May 2014, it was prescribed for a patient with recurrent glioblastoma at UCSF Medical Center." - Anonymous Online Contributor
"This analysis shows that PD-1 inhibitors are associated with very few adverse events. The most frequent were headache, fatigue and constipation. Serious infections are an infrequent but serious side effect of a PD-1 inhibitor. The data also show that treatment of people with PD-1 inhibitors in this population is not harmful and is not associated with any increased mortality." - Anonymous Online Contributor
"In conclusion, pembrolizumab worked as primary treatment in our patient with a combination of previous and progressive relapsing disease even after four years from first infusion. This demonstrates a similar efficacy to that reported with previous therapies. Our case reinforces the hypothesis of efficacy of anti-PD-1 agents in patients previously treated with several lines of chemotherapy, even for patients who are more advanced than our patient." - Anonymous Online Contributor
"• In a recent study, findings indicates that patients with stage 4 glioblastoma have a similar overall survival rate as those with stage 3 glioblastoma. • We conclude that TKI treatment should not be withheld in patients with stage 4 glioblastoma who present to the ED with symptoms of elevated intraventricular pressure. • Larger prospective studies are needed to determine the optimal timing of surgery in patients with stage 3 glioblastoma who present with symptoms of elevated intracranial pressure." - Anonymous Online Contributor